<DOC>
	<DOCNO>NCT00011635</DOCNO>
	<brief_summary>Complementary alternative medicine widely use HIV-infected population . Recent data show serious drug interaction certain complementary medicine protease inhibitor . Silymarin ( Milk thistle ) commonly use dietary supplement HIV-infected patient treatment hepatitis hepato-protectant . Data available suggesting may alter cytochrome P4503A4-mediated drug metabolism . To evaluate effect milk thistle protease inhibitor , indinavir ( IDV ) , ten healthy subject receive IDV ( Crixivan ) alone combination over-the-counter silymarin preparation . IDV initially administer alone dose 800 mg Q8H four dose serial sample collect determination IDV pharmacokinetics morning dose day 2 . Subjects initiate therapy milk thistle use standardized formulation dose three week subject take 4 dos IDV serial sample collect IDV plasma concentration . There 11-day washout period drug , IDV give 4 dos sample collect evaluate offset effect milk thistle . To examine effect milk thistle CYP450 pathway , subject receive single dose caffeine dextromethorphan urine collect milk thistle , washout period . Indinavir , caffeine , dextromethorphan concentration plasma urine determine use validated HPLC method . Steady-state noncompartmental parameter indinavir presence absence milk thistle determine . Pharmacokinetic parameter compare use ANOVA include factor period effect treatment effect . Statistical analysis include calculation mean ratio AUC treatment phase compare IDV alone determination 95 % confidence interval . This study help define drug interaction potential complementary alternative therapy HIV-infected patient .</brief_summary>
	<brief_title>The Effect Milk Thistle Pharmacokinetics Indinavir</brief_title>
	<detailed_description>Complementary alternative medicine widely use HIV-infected population . Recent data show serious drug interaction certain complementary medicine protease inhibitor . Silymarin ( Milk thistle ) commonly use dietary supplement HIV-infected patient treatment hepatitis hepato-protectant . Data available suggesting may alter cytochrome P4503A4-mediated drug metabolism . To evaluate effect milk thistle protease inhibitor , indinavir ( IDV ) , ten healthy subject receive IDV ( Crixivan ) alone combination over-the-counter silymarin preparation . IDV initially administer alone dose 800 mg Q8H four dose serial sample collect determination IDV pharmacokinetics morning dose day 2 . Subjects initiate therapy milk thistle use standardized formulation dose three week subject take 4 dos IDV serial sample collect IDV plasma concentration . There 11-day washout period drug , IDV give 4 dos sample collect evaluate offset effect milk thistle . To examine effect milk thistle CYP450 pathway , subject receive single dose caffeine dextromethorphan urine collect milk thistle , washout period . Indinavir , caffeine , dextromethorphan concentration plasma urine determine use validated HPLC method . Steady-state noncompartmental parameter indinavir presence absence milk thistle determine . Pharmacokinetic parameter compare use ANOVA include factor period effect treatment effect . Statistical analysis include calculation mean ratio AUC treatment phase compare IDV alone determination 95 % confidence interval . This study help define drug interaction potential complementary alternative therapy HIV-infected patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>Age 18 65 year . Healthy medical history physical exam . No concurrent chronic medication , include oral contraceptive . Nonsmoker smoke past 6 month longer . Laboratory value within establish NIAID guideline participation clinical study : AST/SGOT le equal 2 time ULN ; Serum creatinine less equal ULN ; Hemoglobin great equal 10 g/dl . Ability abstain caffeine containing foods/beverages , ethanol , grapefruit grapefruit juice charbroiled food 72 hour prior , day , phenotyping procedure . Ability abstain dextromethorphancontaining counter preparation 72 hour prior , day , phenotyping procedure . No concomitant therapy inhibitor inducer cytochrome P450 mediate drug metabolism within 30 day study ( include grapefruit juice ) . No ingestion dietary supplement within past 30 day . Ability obtain venous access sample collection . No presence lifethreatening unstable renal , hepatic , cardiovascular , hematologic , neurologic , psychiatric , respiratory disease condition may interfere interpretation study result best interest patient opinion investigator . Patients must positive pregnancy test . No presence persistent diarrhea malabsorption would interfere patient 's ability adequately absorb drug . No drug alcohol use may impair safety adherence . No history intolerance milk thistle , indinavir , caffeine , dextromethorphan preparation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>Caffeine</keyword>
	<keyword>Cytochrome P 450</keyword>
	<keyword>Dextromethorphan</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Drug Metabolism</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Milk Thistle</keyword>
</DOC>